business

Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20?

Yahoo Finance · Jun 24, 2026, 1:26 PM · Also reported by 4 other sources

Read full story on Yahoo Finance → More top stories

Also covered by

Investing.com UBS raises Arm Holdings stock price target to $470 on AI chip outlook Investing.com UBS raises AMD stock price target to $670 on server CPU share gains Investing.com Truist raises KB Home stock price target to $56 on margin outlook Investing.com UBS raises JFrog stock price target to $92 on cloud usage trends

Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20?

Also covered by

More in business